Aurinia Pharmaceuticals Announces Voclosporin Meets Primary Endpoint in Phase IIB AURA-LV Study in Lupus Nephritis Aug 15, 2016
Aurinia Pharmaceuticals to Host Lupus Nephritis Expert Breakfast and Webcast on August 4th in New York Jul 28, 2016
Aurinia Announces 24 Week Remission Rates from the First Seven Patients in its Open Label AURION Study in Lupus Nephritis (LN) Jun 28, 2016
Aurinia Announces Presentations at the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Meeting May 12, 2016
